Real-world application of next-generation sequencing-based test for surgically resectable colorectal cancer in clinical practice

<b>Aim:</b> To evaluate the significance of next-generation sequencing-based gene panel testing in surgically resectable colorectal cancer by analyzing real-world data. <b>Materials & methods:</b> A total of 107 colorectal cancer patients who underwent curative surgery were included, and correlations between next-generation sequencing data and clinicopathological findings were evaluated. <b>Results:</b> More combination patterns in gene alteration were identified in advanced-stage tumors than in early-stage tumors. The copy number alteration count was significantly lower in right-sided colon tumors and early-stage tumors. Homologous recombination deficiency was more often identified in advanced-stage tumors, and high homologous recombination deficiency status was useful for identifying high-risk stage II tumors. <b>Conclusion:</b> Homologous recombination deficiency was identified as a useful result of gene panel testing with novel utility in clinical practice.